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Abstract The use of quetiapine for treatment of bipolar disorders at a higher dosage than
the licensed range is not unusual in clinical practice. Quetiapine is predominantly
metabolised by cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP2D6. The
large interindividual variability of those isozyme activities could contribute to the vari-
ability observed in quetiapine dosage. The aim of the present study is to evaluate if the use
of high dosages of quetiapine in some patients, as compared to patients treated with a
dosage in the licensed range (up to 800 mg/day), could be explained by a high activity of
CYP3A4 and/or of CYP2D6. CYP3A4 activities were determined using the midazolam
metabolic ratio in 21 bipolar and schizoaffective bipolar patients genotyped for CYP2D6.
9 patients were treated with a high quetiapine dosage (mean ± SD, median; range:
1467 ± 625, 1200; 1000–3000 mg/day) and 11 with a normal quetiapine dosage
(433 ± 274, 350; 100–800 mg/day). One patient in the high dose and one patient in the
normal dose groups were genotyped as CYP2D6 ultrarapid metabolizers. CYP3A4 activ-
ities were not significantly different between the two groups (midazolam metabolic ratio:
9.4 ± 8.2; 6.2; 1.7–26.8 vs 3.9 ± 2.3; 3.8; 1.5–7.6, in the normal dose group as compared
to the high dose group, respectively, NS). The use of high quetiapine dosage for the
patients included in the present study cannot be explained by variations in pharmacoki-
netics parameters such as a high activity of CYP3A4 and/or of CYP2D6.
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Introduction
Quetiapine was found to be effective in the treatment of acute bipolar mania, both as
monotherapy [1–3] and in combination with other mood stabilizers [4, 5] as well as
monotherapy in bipolar depression [6]. The quetiapine dosage in mania studies was usually
up to 800 mg/day [1–6] and up to 600 mg for the treatment of bipolar depression [6]. The
response rates of groups receiving quetiapine in those studies varied between 43 and 58 %
[1]. Part of the non-response may be due to an inadequate dosage. The use of high-dose of
quetiapine ([800 mg/day) is not unusual in clinical practice, but there are few published
data regarding its efficacy or safety [7]. In a retrospective analysis of 94 patients
with bipolar or schizoaffective bipolar disorder treated in the Department of Psychiatry
(Lausanne, Switzerland) between December 1999 and February 2005, more than thirty
percent received quetiapine at a dosage higher than 800 mg [8]. One can hypothesize that
such dosage variability may be due, in part, to the inter-individual variability of drug
pharmacokinetics.
Quetiapine is predominantly metabolised by cytochrome P450 3A4, whereas CYP2D6
only contributes to a small extent, via quetiapine 7-hydroxylation [9]. Accordingly, que-
tiapine pharmacokinetics was affected when administered with potent CYP3A4 inhibitors
or inducers such as ketoconazole or carbamazepine [10]. The large interindividual vari-
ability of CYP3A4 [11] and/or of CYP2D6 [12] activities could thus contribute to the
variability in quetiapine dosage.
The aim of the current study was to evaluate if high dosages of quetiapine ([800 mg),
when used under routine clinical conditions in a sample of bipolar and schizoaffective
bipolar patients, could be explained in part by high CYP3A4 and/or of CYP2D6 activities,
in comparison with patients treated with a dosage of quetiapine within the licensed range
(B800 mg).
Methods
Patients were recruited from the Department of Psychiatry, Lausanne, Switzerland. During
a 6 months period, all adult patients with bipolar or schizoaffective bipolar disorder, who
were receiving or had received treatment for a major affective episode with quetiapine,
were identified and the study was proposed. Quetiapine was usually introduced during
hospitalization, with a rapid titration scheme (200 mg at day 1, 400 mg at day 2) or less
frequently with a slower titration scheme (50 mg at day 1, 100 mg at day 2). The dosage
was thereafter adjusted (increased or decreased) every 2–7 days, in order to optimize
efficacy and tolerability. The patients were classified respectively as high ([800 mg/day)
and normal quetiapine dosage (B800 mg/day), in accordance with the highest dosage
prescribed to each patient during an actual or past episode.
Hepatic and renal functions were assessed using standard clinical laboratory tests
(alanine amino transferase, aspartate amino transferase, alkaline phosphatase, !-glutam-
yltransferase, and creatinine concentrations). Blood samplings for quetiapine serum/plasma
concentration determinations were performed before the morning medication intake. The
concentrations of quetiapine were determined using a high-pressure liquid chromatography
column (analytical column: EC 125/2 Nucleosil 100-5 C18, 5 lm silica gel, 125 9 2 mm,
Astec, Basel, Switzerland) with a mass spectrometry detector (HP 1100 series, Agilent
Technologies, Palo Alto, CA, U.S.A.) after a liquid–liquid extraction step. The LC con-
ditions were: mobile phase: 35 % tetrahydrofuran: 65 % 4 mM NH4NO3: 1.5 % methanol;
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flow rate: 0.3 ml/min. Analyses were performed in the selected-ion monitoring mode for
the ions at m/z 384.2. The limit of quantification was 0.4 ng/ml. Intra- and interday
coefficients of variation determined at three concentrations ranged from 0.9 to 1.8 % (Eap
et al., unpublished method, detailed method available on request).
CYP3A4 activity was measured using the midazolam metabolic ratio (MR) as previ-
ously described [13, 14]. In summary, following oral administration, midazolam is oxi-
dized to 10-OH midazolam by CYP3A4. The test measures the 10OH-midazolam/
midazolam plasma MR half an hour after oral intake of 0.075 mg of midazolam (8).
Genomic DNA was extracted from EDTA blood samples with the FlexiGene DNA Kit
(Qiagen, Hombrechtikon, Switzerland). Genotyping of CYP2D6 was performed by
real-time polymerase chain reaction with the use of 50-nuclease allelic discrimination
assays (ABI PRISM 7000 Sequence Detection System; Applied Biosystems, Rotkreuz,
Switzerland) with primers and probes obtained from Applied Biosystems for alleles *3, *4,
and *6, and as previously described for the allele *5 and *xN [15, 16].
The following data were recorded from medical charts: baseline demographic and
clinical characteristics, psychiatric diagnosis, concurrent medical illness, current and past
doses of quetiapine. Psychiatric diagnosis was made according to DSMIV criteria by
psychiatry residents and confirmed by a senior psychiatrist. Concomitant medication and
grapefruit juice intake were checked in order to detect potential biases due to inhibition or
induction of CYP3A. The study protocol was approved by the appropriate Ethical com-
mittee and the institutional review board and all subjects gave written informed consent to
participate.
Analysis
Statistical analysis was performed using the SPSS 12.0 program. Group to group com-
parisons were made using the Mann–Whitney U Test. Spearman correlations were carried
out when appropriate. The two sample-binomial test of equal proportion (two-sided) was
used to compare frequencies of variables between the two groups. A p value of less than
0.05 was considered as statistically significant.
Results
Twenty-two patients were identified, but one of them refused to participate in the study.
Consequently, twenty-one patients were included, 9 in the high dose group, 12 in the
normal dose group. All but 3 (1 Black African 2 North Africans) patients were Caucasian,
with 11 female (52 %), and a mean age of 43.5 years (SD: 12 years), all meeting criteria
for bipolar disorder type I (n = 13; 62 %), type II (n = 3; 14 %) or for schizoaffective
bipolar disorder (n = 5; 24 %). A diagnosis of dependence on a substance other than
nicotine was observed in 19 % of the population sample (cannabis, heroin) whereas 76 %
of patients were smokers. Patients with heroin dependence were abstinent during the study,
as assessed by urine screening. Two patients had a history of C hepatitis infection (one in
each dose group), both of them being without symptoms at the time of inclusion. Hepatic
and renal functions were either normal or slightly disturbed (values of alanine amino
transferase, aspartate amino transferase, alkaline phosphatase and !-glutamyltransferase
less than threefold the normal range, value of creatinine less than twofold the normal
range). All but 4 patients received quetiapine at the time of inclusion in the study. Reasons
related to quetiapine cessation were the occurrence of side effects (akathysia, one normal
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dose patient), dizziness (one normal dose patient), refusals of the treatment (one normal
dose patient, one high dose patient).
All patients were taking 1 or more comedications (alprazolam, amisulpride, anethol-
trithione, atorvastatin, bisacodyl, carbamazepine, chlorprothixene, chlortalidonum, clor-
azepate, citalopram, eletriptan, esomeprazole, flurazepam, lamotrigine, lansoprazole,
lithium, lorazepam, macrogolum, methylphenidate, mirtazapine, norfenedrine, olanzapine,
oxazepam, paroxetine, pinaverium, procyclidine, propranolol, simvastatin, sulcrafate, tol-
perisone, topiramate, triethylperazine, valproate, venlafaxine, zolpidem, zuclopenthixol).
With the exception of carbamazepine (one normal dose patient), a strong inducer of
CYP3A4 [11], none of the reported comedications were known to be strong CYP3A4
inhibitors or inducers. The patient treated with carbamazepine had a MR of 6.2, i.e. in the
normal range and not increased as expected [14], associated with a very low quetiapine
serum/plasma concentration (4 ng/ml). He was therefore considered to be non-compliant to
both treatments at the time of the study. For patients who were still treated with quetiapine
at inclusion, quetiapine dosage was correlated with quetiapine trough plasma concentration
(r2 = 0.61, p = 0.0004).
Demographic and metabolic data measured in the high and normal dose groups are
shown in Table 1. The two groups did not differ with regards to the age of the patients (44
vs 43 years, respectively, p = 0.86) nor to the proportion of smokers (78 % vs 75 %,
respectively, p = 0.6. As expected quetiapine doses and blood levels, measured at the
maximum dosage for each patient, were higher (1468 vs 433 mg/day, p = 0.002; 303 vs
64 ng/ml, p = 0.006 respectively) in the high dose group. A higher proportion of patients
in the high dose group were male (78 % vs 25 %, p \ 0.0001).
The MR [mean ± standard deviation; median; (range)] in the whole group was:
[7.0 ± 6.8; 5.5; (1.4–26.8)]. There was a trend (p = 0.06) towards higher CYP3A activity
in the normal dose group as compared to the high dose group MR: 9.4 versus 3.9,
respectively. Excluding the analysis of the four patients who stopped quetiapine or the
patient considered as non-compliant during the study period, did not change the results.
Table 1 Demographic and
metabolic data as determined
in the normal and high dose
group
Data are given as
mean ± standard deviation,





(n = 9) (n = 12)
Age, years 44 ± 12 43 ± 12 0.86
Female (number, frequency) 2 (22 %) 9 (75 %) \0.0001
Smokers (number, frequency) 7 (78 %) 9 (75 %) 0.6
Quetiapine maximum dosage,
mg/day





303 ± 210 64 ± 46 0.006
287 44
14–673 4–126






1 (11 %) 1 (8.3 %) 0.28
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When correcting for multiple tests, only the proportion of male, and the quetiapine doses
and blood concentrations remained significantly different between the normal dose as
compared to the high dose groups.
Finally, when considering the whole group, there was a trend (r = 0.40, p = 0.10)
between quetiapine serum/plasma concentration and CYP3A4 activity, with a decrease in
quetiapine serum/plasma concentration with increasing CYP3A4 activity.
Discussion
The use of quetiapine at doses higher than the licensed range (i.e. [800 mg/day) is not
unusual in clinical practice and the present study aimed to investigate whether the use of such
high doses could be due, at least in part, to a high activity of the two main enzymes involved
in quetiapine metabolism, namely CYP3A4 and CYP2D6 [9]. Two groups of patients were
therefore included, the normal and high dose group having previously received, or receiving
at the time of inclusion, quetiapine at a maximum mean dose of 433 ± 274 mg/day and of
1467 ± 625 mg/day, respectively. At the time of inclusion all patient received comedica-
tions and the two groups did not differ with regards to smoking habit and age. The higher
proportion of female patients in the normal dose (75 %) as compared to the high dose group
(22 %) could tentatively be explained by the fact that, in the presence of non-response,
clinicians will more easily increase quetiapine doses beyond the licensed range in male than
in female. On the other hand, such a difference in the proportion of female between the two
groups is not expected to influence the clearance of quetiapine, as it has been shown that
gender has no effect on the pharmacokinetics of quetiapine [17, 19].
Our results show that a high CYP2D6 activity cannot explain the use of high quetiapine
dosages as one patient in each group was genotyped as being CYP2D6 ultrarapid metab-
olizer. It should however be mentioned that the presently available genotyping methods
allows to detect about only one-fourth of all CYP2D6 ultrarapid metabolizer [18]. An
unequal repartition of ultrarapid metabolizers not detected by the currently used method
can therefore not be excluded. With regard to CYP3A4, the main enzyme involved in
quetiapine metabolism [9], the use of high quetiapine doses can also not be explained by a
high activity of this isozyme. Finally, the correlation observed between the quetiapine
dosage and its serum/plasma concentrations are in agreement with previous reports [9].
Conclusion
In summary, the present study shows that, at least in the population treated in our hospital,
the use of higher than licensed range of quetiapine cannot be explained by a high activity
of CYP3A4 and/or CYP2D6, the two main enzymes involved in quetiapine metabolism.
The present results did not contest that individual patients may receive a high quetiapine
dose in relation to high activity of CYP3A4 and/or of CYP2D6, as suggested by the trend
towards significant negative correlation between quetiapine serum/plasma concentration
and CYP3A4 activity, and by case observations of non-response to quetiapine associated
with very high CYP3A4 and CYP2D6 activities and very low quetiapine plasma levels
(Eap et al. unpublished observation). Further studies are needed to explore the influence of
other genetic variability (e.g. genetic polymorphism of receptors or transporters possibly
involved in quetiapine mechanisms of action) [20, 21] and of clinical factors (e.g. episode
types, episode severity, clinical practice) which could contribute to the interindividual
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variation of administered quetiapine doses for bipolar disorders and for schizoaffective
episodes. As a final comment, it should be stressed that the prescription of drugs at a higher
dosage than the licensed range should be performed only after careful examination of risk/
benefit ratios, and also after taking all necessary measures to ensure their safety (e.g.
Electrocardiogram).
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